Andris Fabienne, Denanglaire Sébastien, Baus Erika, Rongvaux Anthony, Steuve Jonathan, Flavell Richard A, Leo Oberdan
Laboratoire d'Immunobiologie, Institut de Biologie et de Médecine Moléculaire, Université Libre de Bruxelles, Gosselies, Belgium.
J Immunol. 2011 Feb 15;186(4):2245-53. doi: 10.4049/jimmunol.1002333. Epub 2011 Jan 19.
Adjuvant formulations boost humoral responses by acting through several, yet incompletely elucidated pathways. In this study, we show that oligomycin or 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR) enhances Ab production when coinjected with T cell-dependent Ags. Oligomycin and AICAR lead to intracellular ATP reduction, suggesting that metabolic stress could be sensed by immune cells and leads to increased humoral responses. AICAR promotes IL-4 and IL-21 by naive Th cells but does not affect dendritic cell activation/maturation in vitro or in vivo. Accordingly, the adjuvant effect of AICAR or oligomycin does not require MyD88 or caspase-1 expression in vivo. Because AICAR is well tolerated in humans, this compound could represent a novel and safe adjuvant promoting humoral responses in vivo with a minimal reactogenicity.
佐剂配方通过多种尚未完全阐明的途径发挥作用,从而增强体液免疫反应。在本研究中,我们发现,与T细胞依赖性抗原共同注射时,寡霉素或5-氨基咪唑-4-甲酰胺-1-β-D-核糖核苷(AICAR)可增强抗体产生。寡霉素和AICAR导致细胞内ATP减少,这表明免疫细胞可能感知到代谢应激并导致体液免疫反应增强。AICAR可促进初始Th细胞产生IL-4和IL-21,但在体外或体内均不影响树突状细胞的激活/成熟。因此,AICAR或寡霉素的佐剂作用在体内不需要MyD88或caspase-1表达。由于AICAR在人体内耐受性良好,这种化合物可能代表一种新型且安全的佐剂,在体内以最小的反应原性促进体液免疫反应。